Janine Bilsborough

Years Active: 2020-2024
Publications (10 Years): 5

Cedars-Sinai Medical Center

University of Queensland (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Cedars-Sinai Medical Center Jun 01 2012

United States

Director of IBD target discovery :: Medicine/Gastroenterology

Amgen Inc

United States

Senior Scientiest :: Inflammation

Zymogenetics Inc

United States

Scientist :: Autoimmunity and Inflammation

Education History

University of Queensland

Australia

PHD

Publications

Ignat Printsev, Elyas Alalli, Janine Bilsborough
The Opposite Functions of CD30 Ligand Isoforms. Current issues in molecular biology 46 (3) (2024)
Ignat Printsev, Elyas Alalli, Janine Bilsborough
The Opposite Functions of CD30 Ligand Isoforms. Current issues in molecular biology 46 (3) (2024)
Ignat Printsev, Elyas Alalli, Janine Bilsborough
The Opposite Functions of CD30 Ligand Isoforms. Current issues in molecular biology 46 (3) (2024)
Janine Bilsborough, Marie F Fiorino, Bradley W Henkle
Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis. Expert opinion on drug discovery 16 (5) (2020)
Alka A Potdar, Shishir Dube, Takeo Naito, Gregory Botwin, Talin Haritunians, Dalin Li, Shaohong Yang, Janine Bilsborough, Lee A Denson, Mark Daly, Stephan R Targan, Phillip Fleshner, Jonathan Braun, Subra Kugathasan, Thaddeus S Stappenbeck, Dermot P B McGovern
Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease. medRxiv : the preprint server for health sciences (2020)

Janine Bilsborough.css-eqlu8i{font-size:small;padding-left:4px;}